Railway Pension Investments Ltd Has $15.27 Million Holdings in Stryker Corporation $SYK

Railway Pension Investments Ltd cut its stake in Stryker Corporation (NYSE:SYK) by 4.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,600 shares of the medical technology company’s stock after selling 1,900 shares during the period. Railway Pension Investments Ltd’s holdings in Stryker were worth $15,271,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Mid American Wealth Advisory Group Inc. acquired a new stake in shares of Stryker during the 2nd quarter worth approximately $26,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Stryker during the 2nd quarter worth $28,000. Sachetta LLC lifted its position in shares of Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after buying an additional 27 shares during the last quarter. Ridgewood Investments LLC boosted its stake in Stryker by 48.4% in the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after buying an additional 30 shares in the last quarter. Finally, MTM Investment Management LLC bought a new position in Stryker in the second quarter valued at about $38,000. Institutional investors own 77.09% of the company’s stock.

Insider Activity

In related news, Director Ronda E. Stryker sold 276,173 shares of the business’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the sale, the director directly owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. The trade was a 9.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Preston Wendell Wells sold 165 shares of the stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total transaction of $60,370.20. Following the completion of the sale, the chief financial officer owned 6,694 shares in the company, valued at $2,449,200.72. This represents a 2.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 522,118 shares of company stock valued at $185,381,932 over the last quarter. Company insiders own 5.90% of the company’s stock.

Stryker Stock Performance

Shares of SYK opened at $371.29 on Friday. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The firm’s fifty day simple moving average is $368.90 and its two-hundred day simple moving average is $380.26. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The stock has a market capitalization of $141.99 billion, a P/E ratio of 49.18, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last released its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. During the same quarter in the previous year, the company earned $2.87 EPS. Stryker’s quarterly revenue was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on SYK shares. Needham & Company LLC reissued a “buy” rating and issued a $448.00 target price on shares of Stryker in a report on Friday, November 14th. Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Sanford C. Bernstein restated an “outperform” rating on shares of Stryker in a research report on Monday, November 3rd. Weiss Ratings reissued a “hold (c+)” rating on shares of Stryker in a research note on Tuesday. Finally, Wells Fargo & Company upped their price objective on Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a research note on Friday, November 14th. Thirteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $434.37.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.